Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Testing a Claim about Mean: Known Population SD01:11

Testing a Claim about Mean: Known Population SD

3.3K
A complete procedure of testing the hypothesis about a population mean is explained here.
Estimating a population mean requires the samples to be distributed normally. The data should be collected from the randomly selected samples having no sampling bias. The sample size needed to be higher than 30, and most importantly, the population standard deviation should be already known.
In most realistic situations, the population standard deviation is often unknown, but in rare circumstances, when it...
3.3K
Testing a Claim about Population Proportion01:24

Testing a Claim about Population Proportion

4.0K
A complete procedure for testing a claim about a population proportion is provided here.
There are two methods of testing a claim about a population proportion: (1) Using the sample proportion from the data where a binomial distribution is approximated to the normal distribution and (2) Using the binomial probabilities calculated from the data.
The first method uses normal distribution as an approximation to the binomial distribution. The requirements are as follows: sample size is large...
4.0K
Testing a Claim about Standard Deviation01:19

Testing a Claim about Standard Deviation

3.0K
A complete procedure to test a claim about population standard deviation or population variance is explained here.
The hypothesis testing for the claim of population standard deviation (or variance) requires the data and samples to be random and unbiased. The population distribution also must be normal. There is no specific requirement on the sample size as the estimation is based on the chi-square distribution.
As a first step, the hypothesis (null and alternative) concerning the claim about...
3.0K
Testing a Claim about Mean: Unknown Population SD01:21

Testing a Claim about Mean: Unknown Population SD

6.3K
A complete procedure of testing a hypothesis about a population mean when the population standard deviation is unknown is explained here.
Estimating a population mean requires the samples to be approximately normally distributed. The data should be collected from the randomly selected samples having no sampling bias. There is no specific requirement for sample size. But if the sample size is less than 30, and we don't know the population standard deviation, a different approach is used;...
6.3K
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

1.9K
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
1.9K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

840
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
840

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy and Safety of Lumateperone and Other Atypical Antipsychotics Approved as Adjunctive Treatment for Major Depressive Disorder in the United States: A Network Meta-Analysis.

Advances in therapy·2026
Same author

Patient Preferences for Treatment Attributes in Moderate to Severe Chronic Hand Eczema: A Discrete Choice Experiment.

Dermatology and therapy·2026
Same author

Real-world treatment patterns and clinical burden of patients with hereditary angioedema treated with long-term prophylaxis.

Orphanet journal of rare diseases·2026
Same author

Pegcetacoplan Versus Iptacopan for the Treatment of Patients with C3 Glomerulopathy: Indirect Treatment Comparisons.

Advances in therapy·2026
Same author

Real-world outcomes and corticosteroid sparing with mepolizumab for EGPA or HES.

The journal of allergy and clinical immunology. Global·2026
Same author

Treatment Patterns and Economic Burden in Moderate to Severe Chronic Hand Eczema in the USA: A Real-World Retrospective Claims Analysis.

Dermatology and therapy·2026
Same journal

Prescription drug prior authorization: costs to pharmacies and physicians.

The American journal of managed care·2026
Same journal

Combined pharmacotherapy and psychotherapy impact on opioid use disorder treatment.

The American journal of managed care·2026
Same journal

The societal costs of food insecurity: implications for managed care strategies.

The American journal of managed care·2026
Same journal

Availability of hospital financial assistance documents in non-English languages.

The American journal of managed care·2026
Same journal

Real-world weight loss with injectable semaglutide vs dulaglutide for diabetes.

The American journal of managed care·2026
Same journal

Social needs screening and supplemental benefits in Medicare Advantage.

The American journal of managed care·2026
See all related articles

Related Experiment Video

Updated: Feb 14, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.6K

Claims-based risk model for first severe COPD exacerbation.

Richard H Stanford1, Arpita Nag, Douglas W Mapel

  • 1GlaxoSmithKline, 5 Moore Dr, Research Triangle Park, NC 27709.

The American Journal of Managed Care
|February 21, 2018
PubMed
Summary
This summary is machine-generated.

A new model predicts severe chronic obstructive pulmonary disease (COPD) exacerbations using health insurance claims. A higher controller to total ratio (CTR) of COPD medications indicates a lower risk, aiding in risk stratification.

More Related Videos

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.9K
Establishing a Severe Corneal Inflammation Model in Rats Based on Corneal Epithelium Curettage Combined with Corneal Sutures
04:48

Establishing a Severe Corneal Inflammation Model in Rats Based on Corneal Epithelium Curettage Combined with Corneal Sutures

Published on: November 22, 2024

890

Related Experiment Videos

Last Updated: Feb 14, 2026

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.6K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.9K
Establishing a Severe Corneal Inflammation Model in Rats Based on Corneal Epithelium Curettage Combined with Corneal Sutures
04:48

Establishing a Severe Corneal Inflammation Model in Rats Based on Corneal Epithelium Curettage Combined with Corneal Sutures

Published on: November 22, 2024

890

Area of Science:

  • Pulmonary Medicine
  • Health Informatics
  • Predictive Analytics

Background:

  • Chronic obstructive pulmonary disease (COPD) exacerbations significantly impact patient health and healthcare costs.
  • Predictive modeling using health insurance claims data offers a scalable approach to identify at-risk populations.
  • The controller to total COPD treatment (CTR) ratio is a potential metric for assessing adherence and predicting exacerbation risk.

Purpose of the Study:

  • To develop and validate a predictive model for the first severe COPD exacerbation using health insurance claims.
  • To validate the controller medication to total COPD treatment ratio (CTR) as a risk measure.

Main Methods:

  • A predictive model was developed and validated using data from two managed care databases.
  • Risk factors, including CTR, from a baseline year were analyzed to predict severe exacerbations in the subsequent year.
  • Multivariate analysis and C-statistics were employed to evaluate model performance.

Main Results:

  • The analysis included 223,824 patients with COPD.
  • Key risk factors for severe exacerbation included advanced age, oxygen therapy, COPD diagnosis type, high rescue medication use, and prior moderate exacerbations.
  • A CTR of 0.3 or higher was associated with a 14% reduced risk of severe exacerbation. Model C-statistics ranged from 0.711 to 0.714.

Conclusions:

  • A claims-based risk model effectively predicts the likelihood of a first severe COPD exacerbation.
  • The CTR metric shows promise for identifying high-risk COPD patient populations.
  • These findings can inform providers and payers in developing strategies to prevent severe exacerbations and reduce healthcare expenditures.